CA2471436C - Non-sedating barbituric acid derivatives - Google Patents

Non-sedating barbituric acid derivatives Download PDF

Info

Publication number
CA2471436C
CA2471436C CA2471436A CA2471436A CA2471436C CA 2471436 C CA2471436 C CA 2471436C CA 2471436 A CA2471436 A CA 2471436A CA 2471436 A CA2471436 A CA 2471436A CA 2471436 C CA2471436 C CA 2471436C
Authority
CA
Canada
Prior art keywords
lower alkyl
phenyl
substituted
benzyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2471436A
Other languages
English (en)
French (fr)
Other versions
CA2471436A1 (en
Inventor
Dainel A. Moros
Daniella Gutman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of CA2471436A1 publication Critical patent/CA2471436A1/en
Application granted granted Critical
Publication of CA2471436C publication Critical patent/CA2471436C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
CA2471436A 2002-01-30 2003-01-30 Non-sedating barbituric acid derivatives Expired - Fee Related CA2471436C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35227302P 2002-01-30 2002-01-30
US60/352,273 2002-01-30
PCT/US2003/002638 WO2003063872A1 (en) 2002-01-30 2003-01-30 Non-sedating barbituric acid derivatives

Publications (2)

Publication Number Publication Date
CA2471436A1 CA2471436A1 (en) 2003-08-07
CA2471436C true CA2471436C (en) 2011-10-11

Family

ID=27663075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2471436A Expired - Fee Related CA2471436C (en) 2002-01-30 2003-01-30 Non-sedating barbituric acid derivatives

Country Status (6)

Country Link
EP (1) EP1485101A4 (zh)
JP (1) JP2005516052A (zh)
CN (2) CN1291720C (zh)
CA (1) CA2471436C (zh)
IL (1) IL163168A (zh)
WO (1) WO2003063872A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
JP4739760B2 (ja) 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
JP2015092251A (ja) * 2010-10-07 2015-05-14 富士フイルム株式会社 偏光板保護フィルム、偏光板および液晶表示装置
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE946804C (de) * 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) * 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) * 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
US3711607A (en) * 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3900475A (en) * 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2306170A1 (en) * 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
DE60132337T2 (de) * 2000-07-26 2009-02-12 Taro Pharmaceutical Industries Ltd. Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
EP1485101A4 (en) 2006-04-12
CN1291720C (zh) 2006-12-27
CN1896084A (zh) 2007-01-17
JP2005516052A (ja) 2005-06-02
IL163168A (en) 2012-01-31
CN1625401A (zh) 2005-06-08
WO2003063872A1 (en) 2003-08-07
EP1485101A1 (en) 2004-12-15
CA2471436A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US20060035915A1 (en) Non-sedating barbituric acid derivatives
US6525091B2 (en) Substituted diarylureas as stimulators for Fas-mediated apoptosis
EP1123274B1 (en) Substituted phenyl derivatives, their preparation and use
US20140051722A1 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US11529337B2 (en) Method of treating pain
US8158639B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
CA2471436C (en) Non-sedating barbituric acid derivatives
US20070072886A1 (en) Method of treating movement disorders using barbituric acid derivatives
JP5047442B2 (ja) 神経保護剤としての非鎮静バルビツレート化合物
US20230390227A1 (en) Methods of treating disease with dichlorphenamide
AU2001280778A1 (en) Non-sedating barbiturate compounds as neuroprotective agents
EP1366021A2 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
AU2002306618A1 (en) Substituted diarylureas as stimulators for Fas-mediated apoptosis
US7148350B2 (en) Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction
RU2693633C1 (ru) Фармацевтическая композиция для лечения последствий черепно-мозговой травмы и способ её получения (варианты)
ES2355584T3 (es) Agonista de a-2 1-(2,3-dimetil-fenil)-etil-1,3-dihidro-imidazol-imidazol-2-tiona no sedante.
US20050130978A1 (en) Novel crystal of quinoxalinedione derivative anhydride
US20210077437A1 (en) Methods of treating disease with dichlorphenamide
AU2004229086C1 (en) Non-sedating barbiturate compounds as neuroprotective agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150130